Compared with some of his pharmaceutical CEO peers these days, John Lechleiter has his company on a diet. Instead of using a mega-merger to bulk up before the famine that patent expirations will bring on the industry next year,
Lechleiter has Eli Lilly and Co. burning management fat while looking for smaller companies to munch on.
When it comes to health care reform, Eli Lilly and Co. has its derriere exposed more than its drugmaker peers.
My wife, Becky, is alive today because of Lilly and its trial drug Enzastaurin, a great surgeon, and a terrific team of local doctors.
Eli Lilly & Co. executives are making many trips to Washington to argue for 14 years of sales exclusivity for new drugs made
from cells.
An electronic succession-planning system created by Eli Lilly & Co. about seven years ago is sniffing out top talent.
“Group think,” a powerful and controlling force, was present as the Capital Improvement Board built Lucas Oil Stadium and Eli Lilly and Co. developed and marketed Zyprexa.
Indiana Medicaid officials want to take over management of all its patients’ prescription drugs because they say it could save the state as much as $40 million a year.
Lilly executives want to make biotech their top focus.
Eli Lilly and Co. CEO John Lechleiter played a game of pharmaceutical poker with former Lilly Chief Financial Officer Jim
Cornelius—and won.
Generic drug makers drive up the cost of name-brand drugs developed by locally based Eli Lilly and Co. and other pharmaceutical
firms.
Eli Lilly & Co. has filed lawsuits against seven generic drug companies in federal court in Indianapolis, asking a judge to
declare its Cymbalta patent valid and to tell the generic companies to back off.
Retail developers always have been an audacious breed. They spend millions to build shopping centers, confident that tenants will flock to fill the slots they didn’t prelease. To charge ahead these days takes more than the usual dose of intestinal fortitude. Everyone is nervous — from shoppers to lenders to retailers, many of which have […]
Hoping to increase sales in China’s rapidly growing pharmaceutical market, Eli Lilly and Co. is charging ahead
with
plans to invest $100 million in venture capital in the region over the next several years.
Eli Lilly and Co. has written a $6.5 billion IOU to acquire the cancer drugs of ImClone Systems Inc. Cancer drugs are now
the best-selling class of drugs in the world and one of the fastest growing.
Eli Lilly and Co.’s unorthodox efforts to develop new treatments for Alzheimer’s disease–if successful–could usher in
a new approach to drug development. The Indianapolis-based pharmaceutical company announced that a New York
hedge fund, TPG-Axon Capital, will invest up to $325 million to help cover the exorbitant development costs
of two experimental compounds to treat Alzheimer’s disease.
Service Employees International Union Local 3 is backing local janitors as they restart contract negotiations April 16 with
five of the largest janitorial contractors in Indianapolis. SEIU now is taking direct aim at Lilly, health insurer WellPoint
Inc. and even some local hospitals, hoping they will pressure the janitorial contractors to come to terms.
Eli Lilly and Co. hopes to extend the life of its best-seller Zyprexa with a potentially lucrative, long-acting form of the antipsychotic drug. But first, the Indianapolis-based drugmaker must win over a panel of medical experts convened by the U.S. Food and Drug Administration on Feb. 6.
A new leader will guide the city’s largest company in 2008, with some of the biggest challenges in its history on the horizon.
Eli Lilly and Co. announced Dec. 18 that CEO Sidney Taurel will step down March 31 and will be replaced by President John
C. Lechleiter, who has been the heir apparent for more than two years.
When Eli Lilly and Co. CEO Sidney Taurel announced his retirement Dec. 18, he said he was leaving the company in good shape.
And he can cite plenty of evidence to support him. But when Taurel steps down as CEO March 31, he also will leave a legacy
of a languishing stock price and some costly mistakes that some think could have been avoided. “The facts are the facts; I
guess you can’t ignore it. The stock price has been…
John C. Lechleiter, whom Eli Lilly and Co.’s board voted to replace Sidney Taurel as CEO, is known for getting things done
and yet also for being good at analysis and relating to people under him. Taurel will step down at the end of March but remain
chairman until the end of 2008.
